Age-related macular degeneration Trials in San Antonio, United States
Conditions / Age-related macular degeneration / San Antonio, United States
Age-related macular degeneration is a medical condition with active clinical research programs worldwide.
21 total trials for this combination
Showing top 10 of 21 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01940900 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy | TERMINATED | PHASE3 |
| NCT01940887 | A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy | TERMINATED | PHASE3 |
| NCT02358889 | Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration | COMPLETED | PHASE2 |
| NCT00891735 | A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) | COMPLETED | PHASE3 |
| NCT03710564 | Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections | TERMINATED | PHASE3 |
| NCT06190093 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT02727881 | Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD | UNKNOWN | PHASE3 |
| NCT05300724 | An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | — |
| NCT04005352 | Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) | COMPLETED | PHASE3 |
| NCT03834753 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |